Pyritinol

Summary

Pyritinol (CHEMBL488093) is an approved small molecule (ATC N06BX02); indicated across 5 conditions including attention deficit-hyperactivity disorder and anxiety.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06BX02
• Indications: 5 conditions
• Clinical trials: 1
• Chemistry: 368.5 Da · C16H20N2O4S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL488093
Name	Pyritinol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	14190
ATC	N06BX02
Molecular formula	C16H20N2O4S2
Molecular weight	368.5
InChIKey	SIXLXDIJGIWWFU-UHFFFAOYSA-N

SMILES: CC1=NC=C(C(=C1O)CO)CSSCC2=CN=C(C(=C2CO)O)C

IUPAC name: 5-[[[5-hydroxy-4-(hydroxymethyl)-6-methyl-3-pyridinyl]methyldisulfanyl]methyl]-4-(hydroxymethyl)-2-methylpyridin-3-ol

Also known as: NSC-759229, Piritinol, Pyrithioxin, Pyrithioxine, Pyritinol, SID29217898, PYRITINOL, PYRITINOL DIHYDROCHLORIDE

Parent form; salt/anhydrous children: CHEMBL2355482

Patent coverage: 498 distinct patent families (1,497 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,486 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
attention deficit-hyperactivity disorder	4	MONDO:0007743	EFO:0003888
anxiety	3	MONDO:0011918	EFO:0005230
dementia	3	MONDO:0001627	HP:0000726
depressive disorder	3	MONDO:0002050	MONDO:0002050

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02374567	PHASE3	TERMINATED	Pharmacovigilance in Gerontopsychiatric Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).